Spero Therapeutics, Inc. (SPRO)
1.19
-0.07
(-5.56%)
USD |
NASDAQ |
Oct 02, 16:00
1.195
0.00 (0.00%)
After-Hours: 20:00
Spero Therapeutics Net Income (Quarterly) : -9.552M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -9.552M |
| March 31, 2026 | -7.203M |
| December 31, 2025 | 31.52M |
| September 30, 2025 | -7.382M |
| June 30, 2025 | -1.70M |
| March 31, 2025 | -13.87M |
| December 31, 2024 | -20.89M |
| September 30, 2024 | -17.15M |
| June 30, 2024 | -17.86M |
| March 31, 2024 | -12.67M |
| December 31, 2023 | 51.19M |
| September 30, 2023 | -3.205M |
| June 30, 2023 | -11.91M |
| March 31, 2023 | -13.27M |
| December 31, 2022 | 26.77M |
| September 30, 2022 | -11.68M |
| June 30, 2022 | -28.68M |
| March 31, 2022 | -32.83M |
| Date | Value |
|---|---|
| December 31, 2021 | -29.24M |
| September 30, 2021 | -22.52M |
| June 30, 2021 | -18.57M |
| March 31, 2021 | -19.42M |
| December 31, 2020 | -18.58M |
| September 30, 2020 | -18.94M |
| June 30, 2020 | -17.50M |
| March 31, 2020 | -23.26M |
| December 31, 2019 | -24.99M |
| September 30, 2019 | -17.72M |
| June 30, 2019 | -13.15M |
| March 31, 2019 | -5.072M |
| December 31, 2018 | -10.60M |
| September 30, 2018 | -10.46M |
| June 30, 2018 | -9.956M |
| March 31, 2018 | -10.64M |
| December 31, 2017 | -13.87M |
| September 30, 2017 | -9.844M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | -6.012M |
| Fortress Biotech, Inc. | 0.602M |
| Kura Oncology, Inc. | -68.33M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 9.552M |
| EPS Diluted (Quarterly) | -0.1648 |
| Enterprise Value | 20.46M |
| Earnings Yield | 9.17% |
| Operating Earnings Yield | 3.75% |
| Normalized Earnings Yield | 9.790 |